100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
RAC Practice Exam 1 2024 | 93 Questions with 100% Correct Answers | Verified | Latest Update 2024| Graded A+ $13.49   Add to cart

Exam (elaborations)

RAC Practice Exam 1 2024 | 93 Questions with 100% Correct Answers | Verified | Latest Update 2024| Graded A+

 0 view  0 purchase
  • Course
  • RAC
  • Institution
  • RAC

RAC Practice Exam 1 2024 | 93 Questions with 100% Correct Answers | Verified | Latest Update 2024| Graded A+

Preview 4 out of 36  pages

  • November 9, 2024
  • 36
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers
  • RAC
  • RAC
avatar-seller
Examsplug
RAC Practice Exam 1 2024 | 93
Questions with 100% Correct Answers |
Verified | Latest Update 2024| Graded A+



What is the formal early collaboration meeting that was implemented through

the Food and Drug Modernization Act (FDAMA)? - ✔✔Agreement Meeting


The Agreement Meeting is a formal meeting to agree upon the parameters of the

investigational plan. When a meeting


request is received by FDA, the meeting will be held within 30 days. The

agreements made at the meeting are provided in writing to the sponsor and are

binding on FDA. Regulatory Reference: Early Collaboration Meetings Under the

FDA Modernization Act; Final Guidance for Industry and for CDRH Staff

(February 2001).

,A US medical device contract manufacturer has customers for whom it

manufactures medical device components (parts) and finished medical devices.

To date, all products have been either parts for Class II medical devices or Class II

finished medical devices. The manager of new business contacts the regulatory

manager to assess the impact of a possible new customer


involving a Class III device. What is the first question the regulatory manager should

ask in order to begin assessing the impact of Class III on plant operations? -

✔✔Is it a component or device that would be manufactured?




The following biological products are regulated by CBER EXCEPT:


A Immunizing toxoids,


B Monoclonal antibodies for in vitro use,


C Monoclonal antibodies for in vivo use,


D Infusion of animal sourced cells into a hum - ✔✔B




You work for a company that is developing an autologous cellular therapy

product. FDA has informed your company that your product will be regulated as

a

,HCT/P (Human Cells, Tissues and Cellular and Tissue-Based Product). Based on

this information, which of the following regulatory requirements will your

company need to be compliant with when manufacturing


the product? - ✔✔All Subparts of 21 CFR 1271 except Subpart C (Donor Eligibility)




A company has submitted its NDA for review. An NDA amendment can be

submitted to change or add information to a not yet-

approved NDA. When must new safety information be submitted in a safety

update report? - ✔✔Four months after the initial NDA submission (120 day

safety update)




A television advertisement that you have been asked to review prior to release

discusses the benefits of the drug in detail for 25 seconds, and then names all the

major side effects associated with the product in the last five seconds. You should

advise that: - ✔✔The benefits and side effects of the drug should be

presented with the same level of scope, depth and detail.

, At the completion of a Preapproval Inspection where a deficiency was noted, a

meeting is convened to discuss what document? - ✔✔Form FDA 483




Due to market interest, a new strength for an existing combination OTC product

for use in the adult population (labeled as 12 years of age and older) has been

developed, and appropriate data have been gathered to support safety and

efficacy. The existing product is regulated by a final monograph, but does not

contain labeling for use of the new strength in adult populations. What options

could the company utilize to modify the monograph in order to gain FDA approval

to market the new dosing regimen? - ✔✔New Drug Application; Citizen's

Petition; and Time and Extent Application




If a company is planning to market a medical device that is substantially equivalent

to a device marketed before 1976, it can use which regulatory path? -

✔✔510(k)

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller Examsplug. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $13.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

80364 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$13.49
  • (0)
  Add to cart